Acute ischemic stroke (AIS) - Epidemiology Forecast - 2032

Acute ischemic stroke (AIS) - Epidemiology Forecast - 2032

Key Highlights

The incidence of ischemic stroke has been increasing in younger adults, largely driven by a rise in diabetes, obesity, and metabolic syndrome in this age group. A sedentary lifestyle is one of the major risk factors for an ischemic stroke.

Misdiagnosis and delayed diagnosis continue to be challenging for ischemic stroke patients and might lead to a rise in mortality rate.

The 7MM accounted for over 1.5 million cases of acute ischemic stroke in 2022. The US reported the highest number of cases of acute ischemic stroke, with more than 700,000 in 2022, owing to the long-term psychological, physical, and social consequences.

The risk of acute ischemic stroke is similar in men and women in the US. However, in EU4 and the UK, and Japan, it has been found that men are at a higher risk than women.

Assessments showed that the US accounted for less than 600,000 acute ischemic stroke cases in both males and females in 2022. While in Japan, males were affected more, accounting for nearly 100,000 cases compared to females (around 90,000 cases).

DelveInsight’s ‘Acute Ischemic Stroke (AIS) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of acute ischemic stroke (AIS) in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Acute Ischemic Stroke (AIS) Overview

Acute ischemic stroke (AIS) occurs due to the blockage in the artery resulting in reduced blood flow to the brain that damages and interrupts the brain functions. Every year around 5.5 million people die from stroke, making it the world’s second leading cause of death. Moreover, a high burden of morbidity is also seen in stroke patients leaving nearly 50% of stroke survivors disabled. Of total stroke cases, approximately 70–85% of cases are attributed to ischemic stroke. Common signs and symptoms in patients with acute stroke include hemiparesis, sensory deficits, diplopia, dysarthria, and facial droop. Additionally, the symptoms commonly attributed to increased intracranial pressure, such as nausea, vomiting, headache, and blurred or double vision, may also provide evidence supporting a stroke. Based on the etiology, AIS is divided into four subtypes: 20% cardioembolic, 20% atherosclerosis (large artery disease), 25% lacunar (small vessel disease), and 5% other causes.

Continued in the report…..

Acute Ischemic Stroke (AIS) Diagnosis

For the diagnosis of acute ischemic stroke (AIS), detection is emphasized by the term “time is brain” as the delay in diagnosis can impact the treatment choice. The diagnosis is based on clinical features and data collected by tests such as brain imaging (computed tomography/MRI), cardiac imaging (echocardiography, among others), duplex imaging of extracranial arteries, arteriography, and laboratory assessments for a prothrombotic state. Additionally, the National Institutes of Health Stroke Scale (NIHSS) is widely used to assess the neurological severity of acute ischemic stroke. However, early stroke detection is still critical in rural areas and small clinics due to the unavailability of costly diagnostic tools. Also, the delay in diagnosis can worsen stroke and hamper treatment.

Further, atypical presenting symptoms associated with brain stem and cerebellar-posterior circulation can cause over, under, and misdiagnosis of stroke. Additionally, misdiagnosis can be a risk in young patients with ischemic stroke, leading to delayed recognition, preventing thrombolytic therapy, and increasing morbidity and mortality. Hence, misdiagnosis limits the opportunities for a better treatment outcome.

Nevertheless, the advances in diagnostic tools and equipment, continuous efforts in discovering blood-based biomarkers, and improving diagnosis would drive the growth of the acute ischemic stroke market. Heart and stroke screenings in developed countries will also contribute to market growth.

Further details related to country-based variations are provided in the reported…

Acute Ischemic Stroke (AIS) Epidemiology

As the market is derived using a patient-based model, the acute ischemic stroke (AIS) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed incidence cases of acute ischemic stroke, gender-specific cases of acute ischemic stroke, age-specific cases of acute ischemic stroke, type-specific cases of acute ischemic stroke in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2019 to 2032.

Among the 7MM, the US accounted for the highest number of cases of acute ischemic stroke, with more than 700,000 cases, in 2022, owing to the long-term psychological, physical, and social consequences among the population.

Among the EU4 and the UK, Germany accounted for the highest number of acute ischemic stroke cases (around 250,000). On the contrary, Spain accounted for the least cases in 2022.

Assessments showed that the US accounted for less than 600,000 acute ischemic stroke cases in both males and females in 2022. While in Japan, more males were affected by acute ischemic stroke accounting for nearly 100,000 cases, and females for around 90,000 cases in 2022.

In Japan, there were around 60,000 cases of large artery, 58,000 cases of small artery occlusions, 77,000 cases of cardioembolism, and 35,000 cases of other/undetermined types in 2022.

Country-wise Acute Ischemic Stroke Epidemiology

The report includes the total diagnosed incident cases of acute ischemic stroke in the 7MM countries, estimated to be over 1.6 million in 2022. The seven major markets cover the following:

United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Scope of the Report

The acute ischemic stroke (AIS) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.

The Acute Ischemic Stroke (AIS) Epidemiology Report and Model provide an overview of the risk factors and global trends of acute ischemic stroke (AIS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report provides insight into the historical and forecasted patient pool of acute ischemic stroke (AIS) in seven major markets covering the United States, EU4 (Germany, Spain, France, and Italy) and the UK, and Japan.

The report helps recognize the growth opportunities in the 7MM concerning the patient population.

The report assesses the disease risk and burden and highlights the unmet needs of acute ischemic stroke.

The report provides the segmentation of the acute ischemic stroke epidemiology by diagnosed incident cases of acute ischemic stroke in the 7MM.

The report provides the segmentation of the acute ischemic stroke epidemiology by gender-specific cases of acute ischemic stroke in the 7MM.

The report provides the segmentation of the acute ischemic stroke epidemiology by age-specific cases of acute ischemic stroke in the 7MM.

The report provides the segmentation of the acute ischemic stroke epidemiology by type-specific cases of acute ischemic stroke in the 7MM.

KOL Views

To keep up with current market trends, we interviewed KOLs and obtained SME’s opinions through primary research to fill the data gaps and validate our secondary research. Their opinion helped understand and validate current and emerging treatment patterns or acute ischemic stroke (AIS) market trends. This supported the identification of potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Delveinsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as Hotchkiss Brain Institute Europe, MD American Psychiatric Association, Director of Immunology England, MD University of Colorado Anschutz Medical Campus, etc., were contacted. Their opinion helped understand and validate current and emerging therapies and treatment patterns or acute ischemic stroke market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Key Questions Answered

What will be the growth opportunities in the 7MM for the patient population pertaining to acute ischemic stroke?

What are the key findings pertaining to acute ischemic stroke epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?

What would be the total number of patients with acute ischemic stroke across the 7MM forecast period (2019–2032)?

Among the EU4 and the UK, which country will have the highest number of patients during the forecast period (2019–2032)?

At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?

What are acute ischemic stroke’s disease risks, burdens, and unmet needs?

What are the currently available treatments for acute ischemic stroke?

Key Assessments

Patient Segmentation

Disease Risk and Burden

Risk of disease by the segmentation

Factors driving growth in a specific patient population

Geographies Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2019–2032